The latest research, news, and more from GeoInvesting for MEDICURE INC (MPH.V) /companies/mph.v_medicure_inc/overview en-us Tue, 25 Aug 2026 12:30:44 GMT Tue, 25 Aug 2026 12:30:44 GMT 120 60126Fri, 22 Nov 2019 19:55:07 GMTMedicure Inc., a pharmaceutical company, engages in the development and commercialization of therapies for the cardiovascular market in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia; Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure; and ReDS, a non-invasive medical device that provides measurement of lung fluid for the management of congestive heart failure. The company was founded in 1997 and is headquartered in Winnipeg, Canada./companies/mph.v_medicure_inc/overview